Quest Diagnostics INC

Quest Diagnostics reported strong second quarter 2026 financial results, exceeding expectations with significant revenue and EPS growth, and consequently raised its full-year financial outlook.

Quest Diagnostics Incorporated held its 2026 Annual Meeting of Stockholders on May 20, 2026, where shareholders voted on director elections, executive compensation, and auditor ratification.

Quest Diagnostics has successfully issued $500 million in senior notes due 2036 to support general corporate purposes.

Quest Diagnostics has priced a $500 million offering of 5.000% senior notes due 2036 to be used for general corporate purposes, including potential debt repayment.

Quest Diagnostics reported strong first-quarter 2026 financial results, exceeding expectations with significant revenue and EPS growth, leading to an upward revision of full-year guidance.

Quest Diagnostics announced the election of Timothy Wentworth, former CEO of Walgreens Boots Alliance, to its Board of Directors, enhancing its leadership with extensive healthcare and operational expertise.

Quest Diagnostics announces a 10.2% increase in net revenues for Q2 2026, driven by significant volume growth in its Diagnostic Information Services segment.

Quest Diagnostics announced a 9.2% increase in net revenues for Q1 2026, driven by robust growth in its Diagnostic Information Services (DIS) segment.

Quest Diagnostics reports significant revenue and earnings growth in Q3 2025, driven by acquisitions and organic volume, despite increased operating costs and legal charges.

Quest Diagnostics announced robust financial results for the second quarter and first half of 2025, with significant revenue and earnings growth primarily fueled by recent acquisitions and ongoing strategic initiatives.

Quest Diagnostics' Q1 2025 net revenues increased by 12.1% year-over-year, primarily driven by recent acquisitions.

Quest Diagnostics' Q3 2024 results show revenue growth driven by recent acquisitions and organic expansion, despite a slight decrease in operating income.

Quest Diagnostics reported robust financial results for 2025, driven by significant revenue growth, strategic acquisitions, and increased shareholder returns, while navigating evolving healthcare landscapes.

Quest Diagnostics announces its financial results for the fiscal year ended December 31, 2024, showcasing strategic growth through acquisitions and increased shareholder returns.

Quest Diagnostics' 2023 annual report highlights a year of strategic acquisitions and operational adjustments amidst a changing healthcare environment, with net revenues reaching $9.3 billion.

Mark E Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc, sold 1,600 shares of common stock on July 28, 2026 for $235.18 per share.

Karthik Kuppusamy, SVP, Clinical Solutions of Quest Diagnostics Inc, reported a transaction in 37 shares of common stock on July 22, 2026.

Robert B Carter, a Director of Quest Diagnostics Inc, reported a transaction in 11 shares of common stock on July 22, 2026.

Vicky B Gregg, a Director of Quest Diagnostics Inc, received 72 shares of common stock on July 22, 2026.

Patrick Plewman, SVP for Diagnostic Services of Quest Diagnostics Inc, reported a transaction in 46 shares of common stock on July 22, 2026.

Timothy L Main, a Director of Quest Diagnostics Inc, reported a transaction in 21 shares of common stock on July 22, 2026.

Quest Diagnostics Incorporated has filed its proxy statement for the 2026 Annual Meeting of Stockholders, detailing director nominations, executive compensation, and auditor ratification.

Quest Diagnostics released a supplement to its proxy statement to correct a typographical error regarding the number of outstanding shares.

Quest Diagnostics will hold its annual stockholders meeting on May 15, 2025, to vote on director elections, executive compensation, auditor ratification, and a stockholder proposal.

Quest Diagnostics has released its notice of the 2025 Annual Meeting of Stockholders, detailing the agenda and providing information on voting procedures.

Quest Diagnostics will hold its annual stockholders meeting on May 16, 2024, to vote on director elections, executive compensation, auditor ratification, officer exculpation, and a stockholder proposal on climate risk.

Quest Diagnostics is holding its 2024 Annual Meeting of Stockholders to vote on key proposals, including officer exculpation and climate risk management.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, disclosing a beneficial ownership of 5,428,244 shares, representing 4.9% of Quest Diagnostics Inc.'s common stock.

Vanguard Capital Management has reported beneficial ownership of 8,274,567 shares, representing 7.53% of Quest Diagnostics Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.54% in Quest Diagnostics Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Quest Diagnostics Inc. following an internal realignment.

T. Rowe Price Associates, Inc. has reported a 6.5% beneficial ownership stake in Quest Diagnostics Inc. as of June 30, 2025.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, revealing a beneficial ownership of 5.4% of Quest Diagnostics Inc.'s common stock as of March 31, 2025.